National Health (Minimum Stockholding) Determination 2023 (Cth)
Case
No judgment structure available for this case.
PB 65 of 2023
National Health (Minimum Stockholding) Determination 2023
I, Adriana Platona, as delegate of the Minister for Health and Aged Care, make the following determination.
Dated 29 June 2023
Adriana Platona
First Assistant Secretary
Technology Assessment and Access Division
Department of Health and Aged CareContents
Part 1—Preliminary 1
1 Name. ...................................................................................................................................... 1
2 Commencement........................................................................................................................ 1
3 Authority.................................................................................................................................. 1
4 Definitions................................................................................................................................ 1
5 Usual PBS demand.................................................................................................................. 2
Part 2—Minimum stockholding requirement 3
6 Applicable quantity of a brand of a pharmaceutical item........................................................... 3
Schedule 1—Applicable quantity of a brand of a pharmaceutical item 4
Part 1—Preliminary
1 Name
(1) This instrument is the National Health (Minimum Stockholding) Determination 2023.
(2) This instrument may also be cited as PB 65 of 2023.
2 Commencement
(1) Each provision of this instrument specified in column 1 of the table commences, or is taken to have commenced, in accordance with column 2 of the table. Any other statement in column 2 has effect according to its terms.
Commencement information Column 1 Column 2 Column 3 Provisions Commencement Date/Details 1. The whole of this instrument 1 July 2023. 1 July 2023
Note: This table relates only to the provisions of this instrument as originally made. It will not be amended to deal with any later amendments of this instrument.
(2) Any information in column 3 of the table is not part of this instrument. Information may be inserted in this column, or information in it may be edited, in any published version of this instrument.
3 Authority
This instrument is made under subsection 99AEKC(2) of the National Health Act 1953.
4 Definitions
In this instrument:
Act means the National Health Act 1953.
brand has the same meaning as in Part VII of the Act.
data collection period has the same meaning as in the National Health (Pharmaceutical Benefits) Regulations 2017.
pharmaceutical benefit has the same meaning as in Part VII of the Act.
pharmaceutical item has the same meaning as in Part VII of the Act.
pricing quantity has the same meaning as in Part VII of the Act.
usual demand, when used in relation to a brand of a pharmaceutical item, means the usual demand for the brand of the pharmaceutical item within the meaning of section 99AEKC of the Act.
usual PBS demand, when used in relation to a brand of a pharmaceutical item, means the usual PBS demand for the brand of the pharmaceutical item ascertained in accordance with section 5.
5 Usual PBS demand
(1) The usual PBS demand for a brand of a pharmaceutical item for a month in a data collection period for that brand is the number of packs of the brand supplied during the data collection period (the reference period) before the previous data collection period for the brand divided by the number of months in the reference period.
(2) For the purposes of subsection (1) the number of packs of the brand supplied during a data collection period is taken to be:
(a) the number of packs of the brand supplied as pharmaceutical benefits during that period; and
(b) adjusted as if the size of the pack equals the pricing quantity of the brand.
Part 2—Minimum stockholding requirement
6 Applicable quantity of a brand of a pharmaceutical item
For the purposes of subparagraphs 99AEKC(1)(a)(ii) and (1)(b)(ii) of the Act, if a brand of a pharmaceutical item is specified in an item of column 4 of the table in Schedule 1 to this instrument, the quantity ascertained in accordance with column 5 of that item is the applicable quantity of the brand of the pharmaceutical item.
Schedule 1—Applicable quantity of a brand of a pharmaceutical item
Note: See section 6.
| Applicable quantity of a brand of a pharmaceutical item | ||||
| Column 1 Drug | Column 2 Form | Column 3 Manner of administration | Column 4 Brand | Column 5 Applicable quantity |
| Acarbose | Tablet 50 mg | Oral | GLYBOSAY | 2 months stock by reference to usual demand |
| Acarbose | Tablet 100 mg | Oral | GLYBOSAY | 2 months stock by reference to usual demand |
| Alendronic acid with colecalciferol | Tablet 70 mg (as alendronate sodium) with 70 micrograms colecalciferol | Oral | Fosamax Plus | between 1 July 2023 and 31 December 2023—1.5 months stock by reference to usual demand |
| Alendronic acid with colecalciferol | Tablet 70 mg (as alendronate sodium) with 140 micrograms colecalciferol | Oral | Fosamax Plus 70 mg/140 mcg | between 1 July 2023 and 31 December 2023—1.5 months stock by reference to usual demand |
| Allopurinol | Tablet 100 mg | Oral | Allosig | 3 months stock by reference to usual demand |
| Allopurinol | Tablet 100 mg | Oral | Zyloprim | 3 months stock by reference to usual demand |
| Allopurinol | Tablet 300 mg | Oral | Allopurinol APOTEX | between 1 July 2023 and 31 December 2023—5.5 months stock by reference to usual demand |
| Allopurinol | Tablet 300 mg | Oral | Zyloprim | 4 months stock by reference to usual demand |
| Amino acid formula with vitamins and minerals without phenylalanine | Oral gel 85 g, 30 (PKU squeezie) | Oral | PKU squeezie | after 30 November 2023—6 months stock by reference to usual PBS demand |
| Amisulpride | Oral solution 100 mg per mL, 60 mL | Oral | Solian Solution | 4 months stock by reference to usual PBS demand |
| Amitriptyline | Tablet containing amitriptyline hydrochloride 10 mg | Oral | APX-Amitriptyline | between 1 July 2023 and 31 December 2023—5 months stock by reference to usual demand |
| Amitriptyline | Tablet containing amitriptyline hydrochloride 10 mg | Oral | ENTRIP | 4 months stock by reference to usual demand |
| Amitriptyline | Tablet containing amitriptyline hydrochloride 25 mg | Oral | APX-Amitriptyline | (a) between 1 July 2023 and 31 December 2023—4 months stock by reference to usual demand (b) after 31 December 2023—5 months stock by reference to usual demand |
| Amitriptyline | Tablet containing amitriptyline hydrochloride 25 mg | Oral | ENTRIP | 4 months stock by reference to usual demand |
| Amitriptyline | Tablet containing amitriptyline hydrochloride 50 mg | Oral | APX-Amitriptyline | (a) between 1 July 2023 and 31 December 2023—4 months stock by reference to usual demand (b) after 31 December 2023—4.5 months stock by reference to usual demand |
| Amitriptyline | Tablet containing amitriptyline hydrochloride 50 mg | Oral | ENTRIP | (a) between 1 July 2023 and 31 December 2023—4 months stock by reference to usual demand (b) after 31 December 2023—4.5 months stock by reference to usual demand |
| Amoxicillin | Powder for paediatric oral drops 100 mg (as trihydrate) per mL, 20 mL | Oral | Amoxil | 4 months stock by reference to usual PBS demand |
| Amphotericin B | Lozenge 10 mg | Oral | Fungilin | 4 months stock by reference to usual PBS demand |
| Anastrozole | Tablet 1 mg | Oral | Anastrozole FBM | between 1 July 2023 and 31 August 2023—0 months stock by reference to usual demand |
| Aripiprazole | Tablet 10 mg | Oral | APO-Aripiprazole | 3 months stock by reference to usual demand |
| Aripiprazole | Tablet 10 mg | Oral | Aripiprazole generichealth | between 1 July 2023 and 31 August 2023—0 months stock by reference to usual demand |
| Aripiprazole | Tablet 15 mg | Oral | APO-Aripiprazole | 3 months stock by reference to usual demand |
| Aripiprazole | Tablet 15 mg | Oral | Aripiprazole generichealth | between 1 July 2023 and 31 August 2023—0 months stock by reference to usual demand |
| Aripiprazole | Tablet 20 mg | Oral | APO-Aripiprazole | 3 months stock by reference to usual demand |
| Aripiprazole | Tablet 20 mg | Oral | Aripiprazole generichealth | between 1 July 2023 and 31 August 2023—0 months stock by reference to usual demand |
| Aripiprazole | Tablet 30 mg | Oral | APO-Aripiprazole | 3 months stock by reference to usual demand |
| Atenolol | Oral solution 50 mg in 10 mL, 300 mL | Oral | Atenolol-AFT | 4 months stock by reference to usual PBS demand |
| Atenolol | Tablet 50 mg | Oral | APX-Atenolol | 4 months stock by reference to usual demand |
| Atenolol | Tablet 50 mg | Oral | Tensig | 4 months stock by reference to usual demand |
| Atomoxetine | Capsule 10 mg (as hydrochloride) | Oral | APO-Atomoxetine | 3 months stock by reference to usual demand |
| Atomoxetine | Capsule 18 mg (as hydrochloride) | Oral | APO-Atomoxetine | 3 months stock by reference to usual demand |
| Atomoxetine | Capsule 25 mg (as hydrochloride) | Oral | APO-Atomoxetine | 3 months stock by reference to usual demand |
| Atomoxetine | Capsule 40 mg (as hydrochloride) | Oral | APO-Atomoxetine | 3 months stock by reference to usual demand |
| Atomoxetine | Capsule 60 mg (as hydrochloride) | Oral | APO-Atomoxetine | 3 months stock by reference to usual demand |
| Atomoxetine | Capsule 80 mg (as hydrochloride) | Oral | APO-Atomoxetine | 3 months stock by reference to usual demand |
| Atomoxetine | Capsule 100 mg (as hydrochloride) | Oral | APO-Atomoxetine | 3 months stock by reference to usual demand |
| Azithromycin | Powder for oral suspension 200 mg (as dihydrate) per 5 mL, 15 mL | Oral | Zithromax | 4 months stock by reference to usual PBS demand |
| Baclofen | Tablet 10 mg | Oral | APO-Baclofen | 3 months stock by reference to usual demand |
| Betamethasone | Cream 500 micrograms (as dipropionate) per g, 15 g | Application | Diprosone | between 1 July 2023 and 30 September 2023—2 months stock by reference to usual demand |
| Betamethasone | Cream 500 micrograms (as dipropionate) per g, 15 g | Application | Eleuphrat | between 1 July 2023 and 30 September 2023—2 months stock by reference to usual demand |
| Betamethasone | Ointment 500 micrograms (as dipropionate) per g, 15 g | Application | Diprosone | between 1 July 2023 and 30 September 2023—2 months stock by reference to usual demand |
| Betamethasone | Ointment 500 micrograms (as dipropionate) per g, 15 g | Application | Eleuphrat | between 1 July 2023 and 30 September 2023—2 months stock by reference to usual demand |
| Bosentan | Tablet 125 mg (as monohydrate) | Oral | Bosentan APO | 3 months stock by reference to usual demand |
| Calcium | Tablet, chewable, 500 mg (as carbonate) | Oral | Cal-500 | after 30 November 2023—6 months stock by reference to usual PBS demand |
| Candesartan | Tablet containing candesartan cilexetil 4 mg | Oral | APO-Candesartan | between 1 July 2023 and 31 December 2023—5.5 months stock by reference to usual demand |
| Candesartan | Tablet containing candesartan cilexetil 4 mg | Oral | CANDESAN | between 1 July 2023 and 31 December 2023—5.5 months stock by reference to usual demand |
| Candesartan | Tablet containing candesartan cilexetil 8 mg | Oral | APO-Candesartan | between 1 July 2023 and 31 December 2023—5 months stock by reference to usual demand |
| Candesartan | Tablet containing candesartan cilexetil 8 mg | Oral | CANDESAN | between 1 July 2023 and 31 December 2023—5.5 months stock by reference to usual demand |
| Captopril | Oral solution 5 mg per mL, 95 mL | Oral | Capoten | 4 months stock by reference to usual PBS demand |
| Carmellose | Eye drops containing carmellose sodium 10 mg per mL, 15 mL | Application to the Eye | Refresh Liquigel | 4 months stock by reference to usual PBS demand |
| Carmellose | Eye drops containing carmellose sodium 5 mg per mL, 15 mL | Application to the Eye | Refresh Tears Plus | 4 months stock by reference to usual PBS demand |
| Carmellose with glycerin | Eye drops containing carmellose sodium 5 mg with glycerin 9 mg per mL, 15 mL | Application to the Eye | Optive | 4 months stock by reference to usual PBS demand |
| Cefalexin | Capsule 500 mg (as monohydrate) | Oral | APO-Cephalexin | between 1 July 2023 and 31 December 2023—5.5 months stock by reference to usual demand |
| Chloramphenicol | Eye drops 5 mg per mL, 10 mL | Application to the Eye | Chlorsig | 4 months stock by reference to usual PBS demand |
| Chlorpromazine | Tablet containing chlorpromazine hydrochloride 10 mg | Oral | Largactil | between 1 July 2023 and 31 August 2023—0 months stock by reference to usual demand |
| Chlorpromazine | Tablet containing chlorpromazine hydrochloride 25 mg | Oral | Largactil | 4 months stock by reference to usual PBS demand |
| Chlortalidone | Tablet 25 mg | Oral | Hygroton 25 | 4 months stock by reference to usual PBS demand |
| Ciclosporin | Capsule 10 mg | Oral | Neoral 10 | 4 months stock by reference to usual PBS demand |
| Ciclosporin | Capsule 25 mg | Oral | APO-Ciclosporin | 3 months stock by reference to usual demand |
| Ciclosporin | Capsule 50 mg | Oral | APO-Ciclosporin | 3 months stock by reference to usual demand |
| Ciclosporin | Capsule 100 mg | Oral | APO-Ciclosporin | 2.5 months stock by reference to usual demand |
| Ciclosporin | Oral liquid 100 mg per mL, 50 mL | Oral | Neoral | 4 months stock by reference to usual PBS demand |
| Clarithromycin | Powder for oral liquid 250 mg per 5 mL, 50 mL | Oral | Klacid | 4 months stock by reference to usual PBS demand |
| Clonazepam | Oral liquid 2.5 mg per mL, 10 mL | Oral | Rivotril | 6 months stock by reference to usual PBS demand |
| Codeine | Tablet containing codeine phosphate hemihydrate 30 mg | Oral | Aspen Pharma Pty Ltd | 4 months stock by reference to usual PBS demand |
| Dantrolene | Capsule containing dantrolene sodium hemiheptahydrate 25 mg | Oral | Dantrium | 6 months stock by reference to usual PBS demand |
| Desferrioxamine | Powder for injection containing desferrioxamine mesilate 2 g | Injection | DBL Desferrioxamine Mesilate | between 1 July 2023 and 31 July 2023—4 months stock by reference to usual demand |
| Dexamethasone with framycetin and gramicidin | Ear drops containing dexamethasone 500 micrograms (as sodium metasulfobenzoate), framycetin sulfate 5 mg and gramicidin 50 micrograms per mL, 8 mL | Application to the Ear | Sofradex | between 1 July 2023 and 31 December 2023—4.5 months stock by reference to usual demand |
| Diazepam | Oral liquid 10 mg per 10 mL, 100 mL | Oral | Diazepam Elixir | 4 months stock by reference to usual PBS demand |
| Diclofenac | Tablet (enteric coated) containing diclofenac sodium 50 mg | Oral | Fenac | (a) between 1 July 2023 and 31 December 2023—1 month stock by reference to usual demand (b) after 31 December 2023—2 months stock by reference to usual demand |
| Dolutegravir with abacavir and lamivudine | Tablet containing dolutegravir 50 mg with abacavir 600 mg and lamivudine 300 mg | Oral | Triumeq | after 30 November 2023—6 months stock by reference to usual PBS demand |
| Domperidone | Tablet 10 mg | Oral | Motilium | between 1 July 2023 and 31 March 2024—4 months stock by reference to usual PBS demand |
| Doxorubicin - pegylated liposomal | Suspension for I.V. infusion containing pegylated liposomal doxorubicin hydrochloride 20 mg in 10 mL | Injection | Liposomal Doxorubicin SUN | 3 months stock by reference to usual demand |
| Doxorubicin - pegylated liposomal | Suspension for I.V. infusion containing pegylated liposomal doxorubicin hydrochloride 50 mg in 25 mL | Injection | Liposomal Doxorubicin SUN | 3 months stock by reference to usual demand |
| Doxycycline | Tablet 50 mg (as hyclate) | Oral | APX-Doxycycline | between 1 July 2023 and 31 December 2023—5 months stock by reference to usual demand |
| Doxycycline | Tablet 50 mg (as hyclate) | Oral | Doxsig | 4 months stock by reference to usual demand |
| Doxycycline | Tablet 100 mg (as hyclate) | Oral | APX-Doxycycline | (a) between 1 July 2023 and 31 December 2023—4.5 months stock by reference to usual demand (b) after 31 December 2023—5.5 months stock by reference to usual demand |
| Doxycycline | Tablet 100 mg (as hyclate) | Oral | Doxsig | between 1 July 2023 and 31 December 2023—5.5 months stock by reference to usual demand |
| Enalapril | Tablet containing enalapril maleate 5 mg | Oral | Acetec | (a) between 1 July 2023 and 31 December 2023—0 months stock by reference to usual demand (b) after 31 December 2023—2 months stock by reference to usual demand |
| Enalapril | Tablet containing enalapril maleate 5 mg | Oral | APO-Enalapril | 4 months stock by reference to usual demand |
| Enalapril | Tablet containing enalapril maleate 5 mg | Oral | Malean | 4 months stock by reference to usual demand |
| Enalapril | Tablet containing enalapril maleate 10 mg | Oral | APO-Enalapril | 4 months stock by reference to usual demand |
| Enalapril | Tablet containing enalapril maleate 10 mg | Oral | Malean | 4 months stock by reference to usual demand |
| Enalapril | Tablet containing enalapril maleate 20 mg | Oral | APO-Enalapril | 3 months stock by reference to usual demand |
| Enalapril | Tablet containing enalapril maleate 20 mg | Oral | Malean | 3 months stock by reference to usual demand |
| Entecavir | Tablet 1 mg (as monohydrate) | Oral | Entecavir GH | between 1 July 2023 and 31 August 2023—0 months stock by reference to usual demand |
| Escitalopram | Oral solution 20 mg (as oxalate) per mL, 15 mL | Oral | Lexapro | 4 months stock by reference to usual PBS demand |
| Escitalopram | Tablet 10 mg (as oxalate) | Oral | APX-Escitalopram | 4 months stock by reference to usual demand |
| Escitalopram | Tablet 20 mg (as oxalate) | Oral | APX-Escitalopram | 4 months stock by reference to usual demand |
| Esomeprazole | Capsule (enteric) 20 mg (as magnesium) | Oral | Noxicid Caps | between 1 July 2023 and 31 December 2023—2.5 months stock by reference to usual demand |
| Esomeprazole | Capsule (enteric) 40 mg (as magnesium) | Oral | Noxicid Caps | between 1 July 2023 and 31 December 2023—1 month stock by reference to usual demand |
| Ezetimibe with simvastatin | Tablet 10 mg-10 mg | Oral | APO-Ezetimibe/Simvastatin 10/10 | 3 months stock by reference to usual demand |
| Ezetimibe with simvastatin | Tablet 10 mg-10 mg | Oral | EZETORIN | 3 months stock by reference to usual demand |
| Ezetimibe with simvastatin | Tablet 10 mg-10 mg | Oral | Vytorin | between 1 July 2023 and 31 December 2023—2.5 months stock by reference to usual demand |
| Ezetimibe with simvastatin | Tablet 10 mg-10 mg | Oral | Zeklen 10/10 mg | between 1 July 2023 and 31 December 2023—2.5 months stock by reference to usual demand |
| Ezetimibe with simvastatin | Tablet 10 mg-20 mg | Oral | APO-Ezetimibe/Simvastatin 10/20 | 3 months stock by reference to usual demand |
| Ezetimibe with simvastatin | Tablet 10 mg-20 mg | Oral | EZETORIN | 3 months stock by reference to usual demand |
| Ezetimibe with simvastatin | Tablet 10 mg-20 mg | Oral | Vytorin | between 1 July 2023 and 31 December 2023—2.5 months stock by reference to usual demand |
| Ezetimibe with simvastatin | Tablet 10 mg-20 mg | Oral | Zeklen 10/20 mg | between 1 July 2023 and 31 December 2023—2.5 months stock by reference to usual demand |
| Ezetimibe with simvastatin | Tablet 10 mg-40 mg | Oral | APO-Ezetimibe/Simvastatin 10/40 | 3 months stock by reference to usual demand |
| Ezetimibe with simvastatin | Tablet 10 mg-40 mg | Oral | EZETORIN | 3 months stock by reference to usual demand |
| Ezetimibe with simvastatin | Tablet 10 mg-40 mg | Oral | Vytorin | between 1 July 2023 and 31 December 2023—2.5 months stock by reference to usual demand |
| Ezetimibe with simvastatin | Tablet 10 mg-40 mg | Oral | Zeklen 10/40 mg | between 1 July 2023 and 31 December 2023—2.5 months stock by reference to usual demand |
| Ezetimibe with simvastatin | Tablet 10 mg-80 mg | Oral | APO-Ezetimibe/Simvastatin 10/80 | 3 months stock by reference to usual demand |
| Ezetimibe with simvastatin | Tablet 10 mg-80 mg | Oral | EZETORIN | 3 months stock by reference to usual demand |
| Ezetimibe with simvastatin | Tablet 10 mg-80 mg | Oral | Vytorin | between 1 July 2023 and 31 December 2023—2 months stock by reference to usual demand |
| Ezetimibe with simvastatin | Tablet 10 mg-80 mg | Oral | Zeklen 10/80 mg | between 1 July 2023 and 31 December 2023—1.5 months stock by reference to usual demand |
| Felodipine | Tablet 2.5 mg (extended release) | Oral | Felodur ER 2.5 mg | 2.5 months stock by reference to usual demand |
| Felodipine | Tablet 2.5 mg (extended release) | Oral | Plendil ER | 2.5 months stock by reference to usual demand |
| Fentanyl | Transdermal patch 2.1 mg | Transdermal | APO-Fentanyl | (a) between 1 July 2023 and 31 December 2023—3 months stock by reference to usual demand (b) after 31 December 2023—3.5 months stock by reference to usual demand |
| Fentanyl | Transdermal patch 4.2 mg | Transdermal | APO-Fentanyl | 3 months stock by reference to usual demand |
| Fentanyl | Transdermal patch 5.10 mg | Transdermal | Denpax | (a) between 1 July 2023 and 31 December 2023—0 months stock by reference to usual demand (b) after 31 December 2023—2.5 months stock by reference to usual demand |
| Fentanyl | Transdermal patch 8.4 mg | Transdermal | APO-Fentanyl | 3 months stock by reference to usual demand |
| Fentanyl | Transdermal patch 10.20 mg | Transdermal | Denpax | (a) between 1 July 2023 and 31 December 2023—0 months stock by reference to usual demand (b) after 31 December 2023—2.5 months stock by reference to usual demand |
| Fentanyl | Transdermal patch 12.6 mg | Transdermal | APO-Fentanyl | 3 months stock by reference to usual demand |
| Fentanyl | Transdermal patch 16.8 mg | Transdermal | APO-Fentanyl | 3 months stock by reference to usual demand |
| Flucloxacillin | Powder for injection 1 g (as sodium monohydrate) | Injection | Flucil | between 1 July 2023 and 30 November 2023—4 months stock by reference to usual demand |
| Flucloxacillin | Powder for oral liquid 125 mg (as sodium monohydrate) per 5 mL, 100 mL | Oral | Flucil | between 1 July 2023 and 30 November 2023—0 months stock by reference to usual demand |
| Flucloxacillin | Powder for oral liquid 250 mg (as sodium monohydrate) per 5 mL, 100 mL | Oral | Flucil | between 1 July 2023 and 30 November 2023—0 months stock by reference to usual demand |
| Fluconazole | Powder for oral suspension 50 mg in 5 mL, 35 mL | Oral | Diflucan | 4 months stock by reference to usual PBS demand |
| Fluorometholone | Eye drops 1 mg per mL, 5 mL | Application to the Eye | FML Liquifilm | 2 months stock by reference to usual PBS demand |
| Fluorometholone | Eye drops containing fluorometholone acetate 1 mg per mL, 5 mL | Application to the Eye | Flarex | 4 months stock by reference to usual PBS demand |
| Fluoxetine | Capsule 20 mg (as hydrochloride) | Oral | Blooms the Chemist Fluoxetine | between 1 July 2023 and 31 July 2023—0 months stock by reference to usual demand |
| Folic acid | Tablet 500 micrograms | Oral | Foltabs 500 | 4 months stock by reference to usual PBS demand |
| Folic acid | Tablet 500 micrograms | Oral | Megafol 0.5 | 4 months stock by reference to usual PBS demand |
| Folic acid | Tablet 5 mg | Oral | Megafol 5 | 4 months stock by reference to usual PBS demand |
| Fosinopril | Tablet containing fosinopril sodium 10 mg | Oral | APO-Fosinopril | 3 months stock by reference to usual demand |
| Fosinopril | Tablet containing fosinopril sodium 20 mg | Oral | APO-Fosinopril | 3 months stock by reference to usual demand |
| Framycetin | Eye or ear drops containing framycetin sulfate 5 mg per mL, 8 mL | Application to the Eye/Ear | Soframycin | 4 months stock by reference to usual PBS demand |
| Furosemide | Oral solution 10 mg per mL, 30 mL | Oral | Lasix | 4 months stock by reference to usual PBS demand |
| Gabapentin | Capsule 100 mg | Oral | GAPENTIN | between 1 July 2023 and 31 December 2023—3.5 months stock by reference to usual demand |
| Gabapentin | Capsule 300 mg | Oral | GAPENTIN | between 1 July 2023 and 31 December 2023—3 months stock by reference to usual demand |
| Gabapentin | Capsule 400 mg | Oral | GAPENTIN | 3 months stock by reference to usual demand |
| Galantamine | Capsule (prolonged release) 8 mg (as hydrobromide) | Oral | Galantyl | (a) between 1 July 2023 and 31 December 2023—0 months stock by reference to usual demand (b) after 31 December 2023—1.5 months stock by reference to usual demand |
| Galantamine | Capsule (prolonged release) 8 mg (as hydrobromide) | Oral | Gamine XR | 3 months stock by reference to usual demand |
| Galantamine | Capsule (prolonged release) 16 mg (as hydrobromide) | Oral | Gamine XR | 3 months stock by reference to usual demand |
| Galantamine | Capsule (prolonged release) 24 mg (as hydrobromide) | Oral | Gamine XR | 3 months stock by reference to usual demand |
| Gemfibrozil | Tablet 600 mg | Oral | Lipigem | between 1 July 2023 and 31 December 2023—2 months stock by reference to usual demand |
| Glucose and ketone indicator-urine | Test strips, 50 (Keto-Diastix) | For External Use | Keto-Diastix | 4 months stock by reference to usual PBS demand |
| Glucose indicator-urine | Test strips, 50 (Diastix) | For External Use | Diastix | 4 months stock by reference to usual PBS demand |
| Haloperidol | Tablet 500 micrograms | Oral | Serenace | 4 months stock by reference to usual PBS demand |
| Haloperidol | Tablet 1.5 mg | Oral | Serenace | 4 months stock by reference to usual PBS demand |
| Haloperidol | Tablet 5 mg | Oral | Serenace | 4 months stock by reference to usual PBS demand |
| Heparin | Injection 5,000 units (as sodium) in 0.2 ml | Injection | DBL Heparin Sodium | 6 months stock by reference to usual PBS demand |
| Hydralazine | Tablet containing hydralazine hydrochloride 25 mg | Oral | Alphapress 25 | 4 months stock by reference to usual PBS demand |
| Hypromellose | Eye drops 3 mg per mL, 10 mL | Application to the Eye | Genteal | 4 months stock by reference to usual demand |
| Hypromellose | Eye drops 3 mg per mL, 10 mL | Application to the Eye | In a Wink Moisturising | 4 months stock by reference to usual demand |
| Ibuprofen | Tablet 400 mg | Oral | APO-Ibuprofen 400 | between 1 July 2023 and 31 December 2023—5 months stock by reference to usual demand |
| Imatinib | Capsule 100 mg (as mesilate) | Oral | Imatinib-APOTEX | 3 months stock by reference to usual demand |
| Imatinib | Capsule 100 mg (as mesilate) | Oral | Imatinib GH | between 1 July 2023 and 31 August 2023—0 months stock by reference to usual demand |
| Imatinib | Capsule 400 mg (as mesilate) | Oral | Imatinib-APOTEX | 3 months stock by reference to usual demand |
| Indapamide | Tablet containing indapamide hemihydrate 2.5 mg | Oral | Insig | 3 months stock by reference to usual demand |
| Insect allergen extract-honey bee venom | Injection set containing 550 micrograms with diluent | Injection | Hymenoptera Honey Bee Venom | after 30 November 2023—6 months stock by reference to usual PBS demand |
| Insect allergen extract-paper wasp venom | Injection set containing 550 micrograms with diluent | Injection | Hymenoptera Paper Wasp Venom | after 30 November 2023—6 months stock by reference to usual PBS demand |
| Insect allergen extract-yellow jacket venom | Injection set containing 550 micrograms with diluent | Injection | Hymenoptera Yellow Jacket Venom | after 30 November 2023—6 months stock by reference to usual PBS demand |
| Insulin glargine | Injections (human analogue), cartridge, 300 units per mL, 1.5 mL, 3 | Injection | Toujeo Solostar | between 1 July 2023 and 30 November 2023—0 months stock by reference to usual demand |
| Insulin glargine | Injections (human analogue), cartridges, 300 units per mL, 1.5 mL, 5 | Injection | Toujeo Solostar | between 1 July 2023 and 30 November 2023—0 months stock by reference to usual demand |
| Irbesartan with hydrochlorothiazide | Tablet 300 mg-25 mg | Oral | AVSARTAN HCT 300/25 | between 1 July 2023 and 31 December 2023—3 months stock by reference to usual demand |
| Labetalol | Tablet containing labetalol hydrochloride 200 mg | Oral | Trandate | between 1 July 2023 and 30 November 2023—0 months stock by reference to usual demand |
| Lansoprazole | Tablet 15 mg (orally disintegrating) | Oral | APO-Lansoprazole ODT | (a) between 1 July 2023 and 31 December 2023—4 months stock by reference to usual demand (b) after 31 December 2023—4.5 months stock by reference to usual demand |
| Lansoprazole | Tablet 30 mg (orally disintegrating) | Oral | APO-Lansoprazole ODT | 3 months stock by reference to usual demand |
| Latanoprost | Eye drops 50 micrograms per mL, 2.5 mL | Application to the Eye | APO-Latanoprost | 2 months stock by reference to usual demand |
| Latanoprost with timolol | Eye drops 50 micrograms latanoprost with timolol 5 mg (as maleate) per mL, 2.5 mL | Application to the Eye | APO-Latanoprost/Timolol 0.05/5 | 2.5 months stock by reference to usual demand |
| Letrozole | Tablet 2.5 mg | Oral | Letrozole FBM | between 1 July 2023 and 31 August 2023—0 months stock by reference to usual demand |
| Levonorgestrel with ethinylestradiol | Pack containing 21 tablets 150 micrograms-30 micrograms and 7 inert tablets | Oral | Lenest 30 ED | between 1 July 2023 and 31 December 2023—1 month stock by reference to usual demand |
| Lithium | Tablet containing lithium carbonate 250 mg | Oral | Lithicarb | after 30 November 2023—6 months stock by reference to usual PBS demand |
| Lithium | Tablet containing lithium carbonate 450 mg (slow release) | Oral | Quilonum SR | after 30 November 2023—6 months stock by reference to usual PBS demand |
| Losartan | Tablet containing losartan potassium 25 mg | Oral | Cozavan | between 1 July 2023 and 31 August 2023—0 months stock by reference to usual demand |
| Methotrexate | Injection 50 mg in 2 mL vial | Injection | Methotrexate Accord | between 1 July 2023 and 31 July 2023—0 months stock by reference to usual demand |
| Meloxicam | Tablet 7.5 mg | Oral | APX-Meloxicam | between 1 July 2023 and 31 December 2023—5 months stock by reference to usual demand |
| Meloxicam | Tablet 7.5 mg | Oral | MELOBIC | 4 months stock by reference to usual demand |
| Methoxyflurane | Liquid for inhalation 999 mg per g, 3 ml (with inhaler) | Inhalation by mouth | Penthrox | 6 months stock by reference to usual PBS demand |
| Metoprolol | Tablet containing metoprolol tartrate 50 mg | Oral | Metrol 50 | between 1 July 2023 and 31 December 2023—5.5 months stock by reference to usual demand |
| Metoprolol | Tablet containing metoprolol tartrate 100 mg | Oral | Metrol 100 | 4 months stock by reference to usual demand |
| Modafinil | Tablet 100 mg | Oral | Modafin | 3 months stock by reference to usual demand |
| Morphine | Tablet containing morphine sulfate pentahydrate 30 mg | Oral | Anamorph | 3 months stock by reference to usual demand |
| Mycophenolic Acid | Powder for oral suspension containing mycophenolate mofetil 1 g per 5 mL, 165 mL | Oral | CellCept | between 1 July 2023 and 30 September 2023—4 months stock by reference to usual PBS demand |
| Nevirapine | Oral suspension 50 mg (as hemihydrate) per 5 mL, 240 mL | Oral | Viramune | 4 months stock by reference to usual PBS demand |
| Nicorandil | Tablets 10 mg, 60 | Oral | APO-Nicorandil | 2 months stock by reference to usual demand |
| Nicorandil | Tablets 10 mg, 60 | Oral | Ikorel | between 1 July 2023 and 30 November 2023—0 months stock by reference to usual demand |
| Nicorandil | Tablets 10 mg, 60 | Oral | Ikotab | (a) between 1 July 2023 and 31 December 2023—0 months stock by reference to usual demand (b) after 31 December 2023—2 months stock by reference to usual demand |
| Nicorandil | Tablets 20 mg, 60 | Oral | APO-Nicorandil | 2 months stock by reference to usual demand |
| Nicorandil | Tablets 20 mg, 60 | Oral | Ikorel | between 1 July 2023 and 30 November 2023—0 months stock by reference to usual demand |
| Nicorandil | Tablets 20 mg, 60 | Oral | Ikotab | (a) between 1 July 2023 and 31 December 2023—0 months stock by reference to usual demand (b) after 31 December 2023—2 months stock by reference to usual demand |
| Norfloxacin | Tablet 400 mg | Oral | APO-Norfloxacin | 2.5 months stock by reference to usual demand |
| Olanzapine | Tablet 5 mg (orally disintegrating) | Oral | APO-Olanzapine ODT | 3 months stock by reference to usual demand |
| Olanzapine | Tablet 10 mg (orally disintegrating) | Oral | APO-Olanzapine ODT | between 1 July 2023 and 31 December 2023—3.5 months stock by reference to usual demand |
| Olanzapine | Tablet 15 mg (orally disintegrating) | Oral | APO-Olanzapine ODT | between 1 July 2023 and 31 December 2023—3 months stock by reference to usual demand |
| Olanzapine | Tablet 15 mg (orally disintegrating) | Oral | PRYZEX ODT | (a) between 1 July 2023 and 31 December 2023—3 months stock by reference to usual demand (b) after 31 December 2023—3.5 months stock by reference to usual demand |
| Olmesartan | Tablet containing olmesartan medoxomil 20 mg | Oral | OLMERTAN | 3 months stock by reference to usual demand |
| Olmesartan | Tablet containing olmesartan medoxomil 40 mg | Oral | OLMERTAN | (a) between 1 July 2023 and 31 December 2023—3 months stock by reference to usual demand (b) after 31 December 2023—3.5 months stock by reference to usual demand |
| Olmesartan with hydrochlorothiazide | Tablet containing olmesartan medoxomil 20 mg with hydrochlorothiazide 12.5 mg | Oral | APX-Olmesartan/HCTZ | between 1 July 2023 and 31 December 2023—3 months stock by reference to usual demand |
| Olmesartan with hydrochlorothiazide | Tablet containing olmesartan medoxomil 20 mg with hydrochlorothiazide 12.5 mg | Oral | OLMERTAN COMBI 20/12.5 | 3 months stock by reference to usual demand |
| Olmesartan with hydrochlorothiazide | Tablet containing olmesartan medoxomil 40 mg with hydrochlorothiazide 12.5 mg | Oral | OLMERTAN COMBI 40/12.5 | 3 months stock by reference to usual demand |
| Olmesartan with hydrochlorothiazide | Tablet containing olmesartan medoxomil 40 mg with hydrochlorothiazide 25 mg | Oral | OLMERTAN COMBI 40/25 | 3 months stock by reference to usual demand |
| Ondansetron | Syrup 4 mg (as hydrochloride dihydrate) per 5 mL, 50 mL | Oral | Zofran syrup 50 mL | 4 months stock by reference to usual PBS demand |
| Ondansetron | Tablet (orally disintegrating) 4 mg | Oral | Ondansetron ODT Lupin | between 1 July 2023 and 31 August 2023—0 months stock by reference to usual demand |
| Ondansetron | Tablet (orally disintegrating) 8 mg | Oral | Ondansetron ODT Lupin | between 1 July 2023 and 31 August 2023—0 months stock by reference to usual demand |
| Oxazepam | Tablet 30 mg | Oral | APO-Oxazepam | 5.5 months stock by reference to usual demand |
| Oxazepam | Tablet 30 mg | Oral | Murelax | 5 months stock by reference to usual demand |
| Pantoprazole | Sachet containing granules 40 mg (as sodium sesquihydrate) | Oral | Somac | 4 months stock by reference to usual PBS demand |
| Pantoprazole | Tablet (enteric coated) 20 mg (as sodium sesquihydrate) | Oral | APO-Pantoprazole | (a) between 1 July 2023 and 31 December 2023—4.5 months stock by reference to usual demand (b) after 31 December 2023—5.5 months stock by reference to usual demand |
| Pantoprazole | Tablet (enteric coated) 20 mg (as sodium sesquihydrate) | Oral | Pantoprazole APOTEX | between 1 July 2023 and 31 December 2023—5 months stock by reference to usual demand |
| Pantoprazole | Tablet (enteric coated) 20 mg (as sodium sesquihydrate) | Oral | Sozol | between 1 July 2023 and 31 December 2023—5 months stock by reference to usual demand |
| Pantoprazole | Tablet (enteric coated) 40 mg (as sodium sesquihydrate) | Oral | Pantoprazole APOTEX | between 1 July 2023 and 31 December 2023—5.5 months stock by reference to usual demand |
| Pantoprazole | Tablet (enteric coated) 40 mg (as sodium sesquihydrate) | Oral | Sozol | (a) between 1 July 2023 and 31 December 2023—4.5 months stock by reference to usual demand (b) after 31 December 2023—5.5 months stock by reference to usual demand |
| Periciazine | Tablet 2.5 mg | Oral | Neulactil | 4 months stock by reference to usual PBS demand |
| Perindopril | Tablet containing perindopril erbumine 2 mg | Oral | Indosyl Mono 2 | (a) between 1 July 2023 and 31 December 2023—4 months stock by reference to usual demand (b) after 31 December 2023—5 months stock by reference to usual demand |
| Perindopril | Tablet containing perindopril erbumine 4 mg | Oral | Indosyl Mono 4 | (a) between 1 July 2023 and 31 December 2023—4.5 months stock by reference to usual demand (b) after 31 December 2023—5.5 months stock by reference to usual demand |
| Perindopril with amlodipine | Tablet containing 5 mg perindopril arginine with 10 mg amlodipine (as besilate) | Oral | APO-Perindopril Arginine/Amlodipine 5/10 | between 1 July 2023 and 31 December 2023—3 months stock by reference to usual demand |
| Perindopril with indapamide | Tablet containing perindopril erbumine 4 mg with indapamide hemihydrate 1.25 mg | Oral | Indosyl Combi 4/1.25 | (a) between 1 July 2023 and 31 December 2023—4 months stock by reference to usual demand (b) after 31 December 2023—5 months stock by reference to usual demand |
| Perindopril with indapamide | Tablet containing perindopril erbumine 4 mg with indapamide hemihydrate 1.25 mg | Oral | Perindo Combi 4/1.25 | (a) between 1 July 2023 and 31 December 2023—2 months stock by reference to usual demand (b) after 31 December 2023—2.5 months stock by reference to usual demand |
| Permethrin | Cream 50 mg per g, 30 g | Application | Lyclear | after 30 November 2023—6 months stock by reference to usual PBS demand |
| Polyethylene glycol 400 with propylene glycol | Eye drops 4 mg-3 mg per mL, 15 mL | Application to the Eye | Systane | between 1 July 2023 and 31 March 2024—4 months stock by reference to usual PBS demand |
| Polyvinyl alcohol | Eye drops 14 mg per mL, 15 mL | Application to the Eye | Liquifilm Tears | between 1 July 2023 and 31 August 2023—0 months stock by reference to usual demand |
| Polyvinyl alcohol | Eye drops 14 mg per mL, 15 mL | Application to the Eye | PVA Tears | between 1 July 2023 and 31 August 2023—0 months stock by reference to usual demand |
| Probenecid | Tablet 500 mg | Oral | Pro-Cid | after 30 November 2023—6 months stock by reference to usual PBS demand |
| Quinapril | Tablet 10 mg (as hydrochloride) | Oral | APO-Quinapril | 3 months stock by reference to usual demand |
| Quinapril | Tablet 20 mg (as hydrochloride) | Oral | APO-Quinapril | 3 months stock by reference to usual demand |
| Rabeprazole | Tablet containing rabeprazole sodium 10 mg (enteric coated) | Oral | APO-Rabeprazole | 4 months stock by reference to usual demand |
| Rabeprazole | Tablet containing rabeprazole sodium 10 mg (enteric coated) | Oral | Parbezol | 4 months stock by reference to usual demand |
| Rabeprazole | Tablet containing rabeprazole sodium 20 mg (enteric coated) | Oral | APO-Rabeprazole | between 1 July 2023 and 31 December 2023—5 months stock by reference to usual demand |
| Raloxifene | Tablet containing raloxifene hydrochloride 60 mg | Oral | RALOVISTA | 3 months stock by reference to usual demand |
| Ramipril | Capsule 10 mg | Oral | APX-Ramipril | (a) between 1 July 2023 and 31 December 2023—4.5 months stock by reference to usual demand (b) after 31 December 2023—5.5 months stock by reference to usual demand |
| Ramipril | Capsule 10 mg | Oral | Prilace | (a) between 1 July 2023 and 31 December 2023—4.5 months stock by reference to usual demand (b) after 31 December 2023—5.5 months stock by reference to usual demand |
| Ramipril | Tablet 1.25 mg | Oral | Prilace | 2.5 months stock by reference to usual demand |
| Ramipril | Tablet 1.25 mg | Oral | Tryzan Tabs 1.25 | (a) between 1 July 2023 and 31 December 2023—1 month stock by reference to usual demand |
| Ramipril | Tablet 2.5 mg | Oral | APO-Ramipril | between 1 July 2023 and 31 December 2023—5.5 months stock by reference to usual demand |
| Ramipril | Tablet 5 mg | Oral | Prilace | between 1 July 2023 and 31 December 2023—5.5 months stock by reference to usual demand |
| Ramipril with felodipine | Tablet 2.5 mg-2.5 mg (modified release) | Oral | Triasyn 2.5/2.5 | 4 months stock by reference to usual PBS demand |
| Ranitidine | Syrup 150 mg (as hydrochloride) per 10 mL, 300 mL | Oral | Zantac Syrup | 4 months stock by reference to usual PBS demand |
| Risedronic acid | Tablet containing risedronate sodium 150 mg | Oral | APO-Risedronate | 3 months stock by reference to usual demand |
| Risperidone | Tablet 1 mg | Oral | APO-Risperidone | between 1 July 2023 and 31 December 2023—3 months stock by reference to usual demand |
| Risperidone | Tablet 3 mg | Oral | APO-Risperidone | (a) between 1 July 2023 and 31 December 2023—3 months stock by reference to usual demand (b) after 31 December 2023—3.5 months stock by reference to usual demand |
| Risperidone | Tablet 3 mg | Oral | Rispa | 3 months stock by reference to usual demand |
| Risperidone | Tablet 4 mg | Oral | Rispa | between 1 July 2023 and 31 December 2023—3 months stock by reference to usual demand |
| Rosuvastatin | Tablet 5 mg (as calcium) | Oral | APX-Rosuvastatin | between 1 July 2023 and 31 December 2023—5.5 months stock by reference to usual demand |
| Rosuvastatin | Tablet 5 mg (as calcium) | Oral | Crosuva 5 | between 1 July 2023 and 31 December 2023—5.5 months stock by reference to usual demand |
| Rosuvastatin | Tablet 10 mg (as calcium) | Oral | APX-Rosuvastatin | between 1 July 2023 and 31 December 2023—5.5 months stock by reference to usual demand |
| Roxithromycin | Tablet 150 mg | Oral | APX-Roxithromycin | 4 months stock by reference to usual demand |
| Roxithromycin | Tablet 300 mg | Oral | APX-Roxithromycin | (a) between 1 July 2023 and 31 December 2023—4 months stock by reference to usual demand (b) after 31 December 2023—5 months stock by reference to usual demand |
| Roxithromycin | Tablet for oral suspension 50 mg | Oral | Rulide D | between 1 July 2023 and 31 July 2023—0 months stock by reference to usual demand |
| Sodium acid phosphate | Tablet, compound effervescent, equivalent to 500 mg phosphorus | Oral | PHOSPHATE PHEBRA | after 30 November 2023—6 months stock by reference to usual PBS demand |
| Sotalol | Tablet containing sotalol hydrochloride 160 mg | Oral | Cardol | (a) between 1 July 2023 and 31 December 2023—0 months stock by reference to usual demand (b) after 31 December 2023—1.5 months stock by reference to usual demand |
| Sumatriptan | Tablet 50 mg (as succinate) | Oral | APO-Sumatriptan | 4 months stock by reference to usual demand |
| Tacrolimus | Capsule 0.5 mg | Oral | Tacrograf | between 1 July 2023 and 31 December 2023—3 months stock by reference to usual demand |
| Tacrolimus | Capsule 1 mg | Oral | Tacrograf | 3 months stock by reference to usual demand |
| Tacrolimus | Capsule 5 mg | Oral | Tacrograf | 3 months stock by reference to usual demand |
| Telmisartan with hydrochlorothiazide | Tablet 80 mg-25 mg | Oral | Telmisartan HCT GH 80/25 | between 1 July 2023 and 30 September 2023—0 months stock by reference to usual demand |
| Temazepam | Tablet 10 mg | Oral | APO-Temazepam | 2.5 months stock by reference to usual demand |
| Temozolomide | Capsule 180 mg | Oral | Temodal | between 1 July 2023 and 31 December 2023—0 months stock by reference to usual demand |
| Temozolomide | Capsule 250 mg | Oral | Temodal | between 1 July 2023 and 31 December 2023—0 months stock by reference to usual demand |
| Tenofovir with emtricitabine | Tablet containing tenofovir disoproxil fumarate 300 mg with emtricitabine 200 mg | Oral | Tenofovir/Emtricitabine 300/200 APOTEX | 3 months stock by reference to usual demand |
| Thiamine | Tablet containing thiamine hydrochloride 100 mg | Oral | Betavit | 4 months stock by reference to usual PBS demand |
| Topiramate | Tablet 25 mg | Oral | APO-Topiramate | 3 months stock by reference to usual demand |
| Topiramate | Tablet 50 mg | Oral | APO-Topiramate | 3 months stock by reference to usual demand |
| Topiramate | Tablet 100 mg | Oral | APO-Topiramate | 3 months stock by reference to usual demand |
| Topiramate | Tablet 200 mg | Oral | APO-Topiramate | 3 months stock by reference to usual demand |
| Tramadol | Oral drops containing tramadol hydrochloride 100 mg per mL, 10 mL | Oral | Tramal | 4 months stock by reference to usual PBS demand |
| Trandolapril | Capsule 500 micrograms | Oral | Dolapril 0.5 | 2.5 months stock by reference to usual demand |
| Trandolapril | Capsule 1 mg | Oral | Dolapril 1 | 3 months stock by reference to usual demand |
| Trandolapril | Capsule 2 mg | Oral | Dolapril 2 | 3 months stock by reference to usual demand |
| Trandolapril | Capsule 4 mg | Oral | Dolapril 4 | 3 months stock by reference to usual demand |
| Triglycerides - medium chain, formula | Oral powder 400 g (Lipistart) | Oral | Lipistart | after 30 November 2023—6 months stock by reference to usual PBS demand |
| Triglycerides, medium chain | Oral liquid 225 mL, 15 (K.Quik) | Oral | K.Quik | after 30 November 2023—6 months stock by reference to usual PBS demand |
| Valganciclovir | Powder for oral solution 50 mg (as hydrochloride) per mL, 100 mL | Oral | Valcyte | 4 months stock by reference to usual PBS demand |
| Valproic acid | Oral liquid containing sodium valproate 200 mg per 5 mL, 300 mL | Oral | Epilim Liquid | 4 months stock by reference to usual PBS demand |
| Valproic acid | Oral solution containing sodium valproate 200 mg per 5 mL, 300 mL | Oral | Epilim Syrup | 4 months stock by reference to usual PBS demand |
| Valproic acid | Tablet, crushable, containing sodium valproate 100 mg | Oral | Epilim | 4 months stock by reference to usual PBS demand |
| Voriconazole | Powder for oral suspension 40 mg per mL, 70 mL | Oral | Vfend | 4 months stock by reference to usual PBS demand |
Actions
Download as PDF
Download as Word Document
Cases Citing This Decision
0
Cases Cited
0
Statutory Material Cited
0